Диссертация (1140250), страница 20
Текст из файла (страница 20)
Kidney Dis. 1985. Т. 5. № 2. С. 97–103.66.Campese V.M. Pathophysiology of resistant hypertension in chronic kidneydisease // Semin Nephrol. – 2014.- Vol.34, №5.- Р.571-576.67.Chen N., Wang W., Huang Y., et al. Community-based study on CKD subjectsand the associated risk factors // Nephrol Dial Transplant.- 2009.- Vol. 24.- Р.2117–2123.12568.Chien K., Lin H., Lee Ch, Hsu H., Lee Y., Chen M. A Prediction Model for theRisk of Incident Chronic Kidney Disease // The American Journal of Medicine.2010.- Vol.123.- Р.
836-84669.Constantine G.R., Ranasinghe P., Weeratunga P., et al. Addition of Propranolol inResistant Arterial hypertension Treatment (APROPRIATE study): study protocolfor a randomized double-blind placebo-controlled trial // Trials. – 2017.- Vol.18,№1.- Р.124.70.CoreshJ., TurinT.C., MatsushitaK., SangY., BallewS.H.,etal.CKD Prognosis Consortium. Decline in estimated glomerular filtration rate andsubsequent risk of end-stage renal disease and mortality // JAMA. – 2014.- Vol.311, №24.- Р.2518-2531.71.Coresh J., Selvin .E, Stevens L.A., et al. Prevalence of chronic kidney disease inthe United States // JAMA.- 2007.- Vol.
298.- Р. 2038–2047.72.Couser W.G., Remuzzi G., Mendis S., Tonelli M. The contribution of chronickidney disease to the global burden of major non-communicable diseases //Kidney Int.- 2011.- Vol. 80.- Р. 1258–1270.73.Chong K., Unruh M.
Why does quality of life remain an under-investigated issuein chronic kidney disease and why is it rarely set as an outcome measure in trialsin this population? // Nephrol Dial Transplant. – 2017.- Vol. 32(suppl 2).-ii47ii52.74.Chronic Kidney Disease Prognosis Consortium, Matsushita K., van der Velde M,et al. Association of estimated glomerular filtration rate and albuminuria with allcause and cardiovascular mortality: a collaborative meta-analysis // Lancet.2010.- Vol.
375.- Р. 2073–2081.75.Crews D.C., Plantinga L.C., Miller E.R. et al. Prevalence of chronic kidneydisease in persons with undiagnosed or prehypertension in the United States.Hypertension.- 2010.- Vol. 55.- Р. 1102—1109.12676.Dale A., Hartley P., Goldacre B.; COMPare project team. PATHWAY-2:spironolactone for resistant hypertension // Lancet.
-2016.- Vol.387(10026).Р.1372-1373.77.Davenport A.P., Hyndman K.A., Dhaun N., Southan C., Kohan D.E., et al.Endothelin // Pharmacol Rev. – 2016.- Vol.68, №2.- Р.357-418.78.DCCT/EDIC Research Group, de Boer IH, Sun W, et al. Intensive diabetestherapy and glomerular filtration rate in type 1 diabetes // N Engl J Med.- 2011.Vol. 365.- Р. 2366–2376.79.Desai A.S., Toto R., Jarolim P., Uno H., Eckardt K.U., Kewalramani R., et al.Association between cardiac biomarkers and the development of ESRD in patientswith type 2 diabetes mellitus, anemia, and CKD // Am J Kidney Dis. – 2011.- Vol.58.- Р.717-728.80.Devraj R., Gordon E.J.
Health literacy and kidney disease: toward a new line ofresearch // Am J Kidney Dis. - 2009 .- Vol.53, №5.- Р.884-889.81.Digne-Malcolm H., Frise M.C., Dorrington K.L. How Do Antihypertensive DrugsWork? Insights from Studies of the Renal Regulation of Arterial Blood Pressure //Front Physiol.- 2016.- Vol.29, №7.- Р.320.82.Dienemann T., Fujii N., Orlandi P., Nessel L. et al. International Network ofChronic Kidney Disease cohort studies (iNET-CKD): a global network of chronickidney disease cohorts //BMC Nephrol. – 2016.- Vol.17, №1.- Р.121.83.Diamantidis C.J., Becker S. Health information technology (IT) to improve thecare of patients with chronic kidney disease (CKD) // BMC Nephrol.- 2014.- Vol.15.- Р. 7.84.Dimitrov B.D., Ruggenenti P., Stefanov R., Perna A., Remuzzi G. Chronicnephropathies: individual risk for progression to end-stage renal failure aspredicted by an integrated probabilistic model // Nephron Clin Pract.- 2003.- Vol.95.- Р.47-59.12785.Donazzan L.
и др. Drug therapy for the patient with resistant hypertension. //Future Cardiol. 2015. Т. 11. № 2. С. 191–202.86.Drawz P.E., Archdeacon P., McDonald C.J., et al. CKD as a model for improvingchronic disease care through electronic health records // Clin J Am Soc Nephrol.2015.- Vol. 10.- Р. 1488–1499.87.DrexlerY.R., BombackA.S.Definition,identificationandtreatmentof resistant hypertension in chronic kidney disease patients // Nephrol DialTransplant. – 2014.- Vol. 29, №7.- Р.1327-1335.88.Duru O.K., Vargas R.B., Kermah D. et al.
High prevalence of stage 3 chronickidney disease in older adults despite normal serum creatinine // J. Gen. Intern.Med. – 2009.- Vol. 24.- Р. 86—92.89.ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force forthe management of dyslipidaemias of the European Society of Cardiology (ESC)and the European Atherosclerosis Society (EAS) // Eur Heart J. – 2011. – Vol. 32.–P. 1769–1818.90.Ewen S., Böhm M., Mahfoud F. Long-Term Follow-Up of BaroreflexActivation Therapy in Resistant Hypertension: Another Piece of the Puzzle?//Hypertension.- 2017.- Vol.69, №5.- Р.782-784.91.Erez G., Selman L., Murtagh F.E.
Measuring health-related quality of life inpatients with conservatively managed stage 5 chronic kidney disease: limitationsof the Medical Outcomes Study Short Form 36: SF-36 // Qual Life Res. – 2016.Vol. 25, №11.- Р.2799-2809.92.Following the Political Declaration on Noncommunicable Diseases (NCDs)adoptedbytheUNGeneralAssemblyin2011,http://www.euro.who.int/ru/health-topics/health-policy/health-2020-the-europeanpolicy-for-health-and-well-being12893.Fox C.S.
Associations of kidney disease measures with mortality and end-stagerenal disease in individuals with and without diabetes: a meta-analysis. // Lancet.2012.- Т. 380, № 9854.- С. 1662–1673.94.Fraccaro P., van der Veer S., Brown B., Prosperi M., O’Donoghue D., Collins G.,Buchan I., Peek N. An external validation of models to predict the onset ofchronic kidney disease using population-based electronic health records fromSalford, UK // BMC Medicine.-2016.- Vol.14.- Р. 104.95.Fried L.F., Emanuele N., Zhang J.H., et al. Combined angiotensin inhibition forthe treatment of diabetic nephropathy // N Engl J Med.- 2013.- Vol. 369.- Р.1892–1903.96.Garofalo C., Borrelli S., Pacilio M., Minutolo R., Chiodini P., De Nicola L., ConteG.
Hypertension and Prehypertension and Prediction of Development ofDecreased Estimated GFR in the General Population: A Meta-analysis of CohortStudies // Am J Kidney Dis. 2016.- Vol. 67, №1.- Р.89-97.97.GBD 2015 DALYs and HALE Collaborators. Global, regional, and nationaldisability-adjusted life-years (DALYs) for 315 diseases and injuries and healthylife expectancy (HALE), 1990–2015: a systematic analysis for the Global Burdenof Disease Study 2015 // Lancet.- 2016.- Vol. 388.- Р.1603–1658.98.Gheewala P.A., Zaidi S.T., Jose M.D., Bereznicki L., Peterson G.M., CastelinoR.L.
Effectiveness of targeted screening for chronic kidney disease in thecommunity setting: a systematic review // J Nephrol. - 2017 [Epub ahead of print]99.Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C. Chronic kidney diseaseand the risks of death, cardiovascular events, and hospitalization // N Engl J Med.2004.- Vol. 351.- Р. 1296–1305.100. Goto M., Wakai K., Kawamura T., Ando M., Endoh M., Tomino Y.
A scoringsystem to predict renal outcome in IgA nephropathy: a nationwide 10-yearprospective cohort study // Nephrol Dial Transplant.-2009.- Vol. 24.- Р.30683074.129101. Grams M.E., Juraschek S.P., Selvin E., et al. Trends in the prevalence ofreduced GFR in the United States: a comparison of creatinine-and cystatinC−based estimates // Am J Kidney Dis.- 2013.- Vol. 62.- Р. 253–260.102.
Grams M.E., Rebholz C., MacMahon B., et al. Identification of incident CKDstage 3 in research studies // Am J Kidney Dis.- 2014.- Vol. 64.- Р. 214–221.103. Halbesma N., Jansen D., Heymans M., Stolk R., de Jong P., Gansevoort R.Development and Validation of a General Population Renal Risk Score // Clin JAm Soc Nephrol.-2011.- Vol.6.- Р.1731–1738.104.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
